Qaim SM, Spahn I. Development of novel radionuclides for medical applications.
J Labelled Comp Radiopharm 2017;
61:126-140. [PMID:
29110328 DOI:
10.1002/jlcr.3578]
[Citation(s) in RCA: 27] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/22/2017] [Revised: 10/20/2017] [Accepted: 10/24/2017] [Indexed: 11/12/2022]
Abstract
Medical radionuclide production technology is well established. There is, however, a constant need for further development of radionuclides. The present efforts are mainly devoted to nonstandard positron emitters (eg, 64 Cu, 86 Y, 124 I, and 73 Se) and novel therapeutic radionuclides emitting low-range β- particles (eg, 67 Cu and 186 Re), conversion or Auger electrons (eg, 117m Sn and 77 Br), and α particles (eg, 225 Ac). A brief account of various aspects of development work (ie, nuclear data, targetry, chemical processing, and quality control) is given. For each radionuclide under consideration, the status of technology for clinical scale production is discussed. The increasing need of intermediate-energy multiple-particle accelerating cyclotrons is pointed out.
Collapse